EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: Focus on anti-neutrophil cytoplasm antibody-associated vasculitis

Annals of the Rheumatic Diseases

Volumn 66, Issue 5, 2007, Pages 605-617

  Hellmich, Bernhard ^b   Flossmann, Oliver ^c   Gross, Wolfgang L ^b   Bacon, Paul ^d   Cohen Tervaert, Jan Willem ^e   Guillevin, Loic ^f   Jayne, David ^c   Mahr, Alfred ^f   Merkel, Peter A ^g   Raspe, Heiner ^b   Scott, David G I ^h   Witter, James ⁱ   Yazici, Hasan ^j   Luqmani, Raashid A ^a,k  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f University of Paris Descartes ^*  (France)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF EAST ANGLIA   (United Kingdom)

ⁱ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^j ISTANBUL UNIVERSITY   (Turkey)

^k UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ANCA ASSOCIATED VASCULITIS; ARTICLE; CLINICAL TRIAL; DELPHI STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; EVIDENCE BASED PRACTICE; HEALTH STATUS; HUMAN; IMMUNOFLUORESCENCE; MEDICAL PROFESSION; MEDICAL SOCIETY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; SYSTEMIC VASCULITIS; UNITED STATES;

ANTIBODIES; BIOLOGICAL MARKERS; CLINICAL TRIALS; CYTOPLASM; EUROPE; GUIDELINES; HUMANS; INTERNATIONAL COOPERATION; NEUTROPHILS; QUALITY OF LIFE; RECURRENCE; REMISSION INDUCTION; RESEARCH DESIGN; TREATMENT OUTCOME; VASCULITIS;

EID: 34248218149     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.062711     Document Type: Article

References (89)

1. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasm antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
2. Jayne D, Rasmussen N, Andrassy K, Bacon P, Cohen Tervaert JW, Dodoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasm autoantibodies. N Engl J Med 2003;349:36-44.
3. The Wegener's Granulomatosis Etanercept (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
4. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309-18.
5. Dougados M, Betteridge N, Burmesfer GR, Euller-Ziegler L, Guillemin F. EULAR standardised operating procedures for the elaboration, evaluation, dissemination and implementation of recommendations endorsed by the EULAR standing commitees. Ann Rheum Dis 2004;63:1172-6.
6. Zochling J, van der Heijde D, Dougados M, Braun J. The process of producing recommendations for rheumatic diseases - what is the evidence? Ann Rheum Dis 2005;24:24.
7. Directive 2001/20/EC of the European Parliament and the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member stales relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Communities 2001;L121:34-44.
8. Lassere MN, Johnson KR, Boers M, Carlton K, Day RO, de Wit M, et al. Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update. J Rheumatol 2005;32:2037-41.
9. Commission regulation no. 507/2006 of 29 March 2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of regulation (EC) No 726/2004 of the European Parliament and of the Council. Off J Eur Union 2006;L92:6-7.
10. While B, Bauer EA, Goldsmith LA, Hochberg MC, Katz LM, Korn JH, et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum 1995;38:351-60.
11. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999;318:593-6.
12. Adu D, Pall A, Luqmani RA, Richards NT, Howie AJ, Emery P, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997;90:401-9.
13. de Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Nolle B, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/ sulfamethoxazole. Arthritis Rheum 1996;39:2052-61.
14. Gayraud M, Guillevin L, Cohen P, Lhote F, Cacoub P, Deblois P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997;36:1290-7.
15. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:106-14.
16. Chevalet P, Barrier JH, Pettier P, Magadur-Joly G, Pottier MA, Hamidou M, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000;27:1484-91.
17. Guillevin L, Jarrousse B, Lok C, Lhote F, Jais P, Le Thi Huong Du D, et al. Longterm-followup after treatment of polyarteriitis nodosa and Chrug-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. J Rheumatol 1991;18:567-74.
18. Guillevin L, Lhote F, Cohen F, Jarousse B, Lortholary O, Genereau T, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteriitis nodosa and Chrug-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995;38:1638-45.
19. Guillevin L, Fain O, Lhote F, Jarrousse B, Le Thi Huong D, Bussel A, et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteriitis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum 1992;35:208-15.
20. Merkel PA, Seo P, Aries P, Neogi T, Villa-Forte A, Boers M, et al. Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. J Rheumatol 2005;32:2488-95.
21. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003;41:776-84.
22. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasm antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004;51:269-73.
23. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000;43:1021-32.
24. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26-37.
25. de Groot K, Jayne D, Tesar V, Savage C. Randomised controlled trial of daily oral versus pulse cyclophosphamide lor induction of remission in ANCA-associated systemic vasculitis [abstract]. Kidney Blood Press Res 2005;28:195.
26. The WGET Research Group. Design of the Wegener's granulomatosis etanercept trial (WGET). Control Clin Trials 2002;23:450-68.
27. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2005;13:13.
28. Jayne D, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000;93:433-9.
29. Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002;41:1303-7.
30. Birck R, Warnatz K, Lorenz HM, Choi M, Haubitz M, Grunke M, et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003;14:440-7.
31. Aries PM, Hellmich B, Both M, Nolle B, Voswinkel J, Holl-Ulrich K, et al. Lack of efficacy of Rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006;65:853-8.
32. Schmitt WH, Birck R, Heinzel P, Gobel U, Choi M, Warnatz K, et al. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant 2005;20:1083-92.
33. Schmitt W, Hagen E, Neumann I, Nowack R, Flores-Suarez LF, van der Woude F. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004;65:1440-8.
34. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 2004;15:717-21.
35. Guillevin L, Cordier J, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-98.
36. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 2002;41:1126-32.
37. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
38. de Groot K, Adu D, Savage C. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001;16:2018-27.
39. Jayne DR, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000;93:433-9.
40. Haubitz M, Schellong S, Gobel U, Schurek HJ, Schaumann D, Koch KM, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasm antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998;41:1835-44.
41. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996;335:16-20.
42. Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001;19:495-501.
43. Kallenberg CG, Tervaert JW, Stegeman CA. Criteria for disease activity in Wegener's granulomatosis: a requirement for longitudinal clinical studies. APMIS Suppl 1990;19:37-9.
44. Whiting-O'Keefe QE, Stone JH, Hellmann DB. Validity of a vasculitis activity index for systemic necrotizing vasculitis. Arthritis Rheum 1999;42:2365-71.
45. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-8.
46. Luqmani RA, Exley AR, Kitas GD, Bacon PA. Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol 1997;11:423-46.
47. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001;44:912-20.
48. Guillevin L, Cohen P, Mahr A, Arene J, Mouthon L, Puechal X, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cylophosphamide pulses in sixty-five patients. Arthritis Rheum 2003;49:93-100.
49. Merkel PA, Cuthbertson D, Hellmich B, Hoffman G, Jayne D, Kallenberg CG, et al. Comparison of disease activity measures for ANCA-associated vasculitis. Arthritis Rheum 2004;50:S229-30.
50. de Groot K, Gross W, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001;55:31-8.
51. Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology 2004;63:339-40.
52. Metzler C, Hellmich B, Gause A, Gross WL, de Groot K. Churg Strauss syndrome-successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004;22(Suppl 36):S52-61.
53. Reinhold-Keller E, Fink C, Herlyn K, Gross WL, de Groot K. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Care Res 2002;47:326-32.
54. Eisenberger U, Fakhouri F, Vanhille P, Beaufils H, Mahr A, Guillevin L, et al. ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant 2005;20:1392-9.
55. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001;44:1149-54.
56. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.
57. Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005;52:2168-78.
58. Hoffman G, Kerr G, Leavitt R, Hallahan C, Lebovics R, Travis W, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-99.
59. Koutantji M, Harrold E, Lane SE, Pearce S, Watts RA, Scott DG. Investigation of qualify of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum 2003;49:826-37.
60. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gutfleisch J, Peter HH, Raspe HH, et al. Effect of Wegener's granulomatosis on work disability, need for medical care, and quality of life in patients younger than 40 years at diagnosis. Arthritis Rheum 2002;47:320-5.
61. McHorney CA, Ware JE Jr, Rogers W, Raczek AE, Lu JF. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. Med Care 1992;30(Suppl):MS253-65.
62. Luqmani R, Bacon P, Rasmussen N, Jayne D. Validation of the Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials. Arthritis Rheum 2000;43(Suppl):S574.
63. Rao J, Allen N, Pincus N. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med 1998;129:345-52.
64. Sorensen S, Slot O, Tvede N, Petersen J. A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature. Ann Rheum Dis 2000;59:478-82.
65. Leavitt R, Fauci A, Bloch D, Michel B, Hunder G, Arend W, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-7.
66. Jennette JC, Folk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187- 92.
67. Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997;72:737-47.
68. Jayne D. Update on the European Vasculitis Study Group (EUVAS). Curr Opin Rheumatol 2001;13:48-55.
69. Jayne D. Evidence-based treatment of systemic vasculitis. Rheumatology (Oxford) 2000;39:585-95.
70. Gaskin G, Savage CO, Ryan JJ, Jones S, Rees AJ, Lockwood CM, et al. Anti-neutrophil cytoplasm antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991;6:689-94.
71. Mahr A, Girard T, Agher R, Guillevin L. Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. Rheumatology 2001;40:492-8.
72. Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. QJM 2005;98:97-111.
73. Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 2004;19:1403-11.
74. Bligny D, Mahr A, Toumelin PL, Mouthon L, Guillevin L. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients Arthritis Rheum 2004;51:83-91.
75. Guillevin L, Le Thi Huong D, Godeau P, Jais P, Wechsler B. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients. Br J Rheumatol 1988;27:258-64.
76. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churq-Strauss syndrome Medicine 1996;75:17-28.
77. Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001;44:666-75.
78. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Carruthers DM, Moots R. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol 1998;37:57-63.
79. Goskin G, Jayne D. Adjuctive Piasmaexchange is superior to methylprednisolone in acute renale failure due to ANCA-associated glomerulonephritis. J Am Soc Nephrol 2002;13:F-FC010.
80. Savige J, Pollock W, Trevisin M. What do antineutrophil cytoplasm antibodies tell us? Best Pract Res Clin Rheumatol 2005;19:263-76.
81. Holle JU, Hellmich B, Backes M, Gross WL, Csernok E. Variations in performance characteristics of commercial enzyme immunoassay kits for the detection of antineutrophil cytoplasmatic antibodies: what is the optimal cut-off? Ann Rheum Dis 2005;64:1773-9.
82. Csernok E, Holle J, Hellmich B, Cohen Tervaert J, Kallenberg C, Limburg P, et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3 in Wegener's granulomatosis: first results from a multicenter study. Rheumatology 2004;43:174-80.
83. Reinhold-Keller E, de Groot K, Holl-Ulrich K, Arlt AC, Heller M, Feller AC, et al. Severe CNS manifestations as the clinical hallmark in generalized Wegener's granulomatosis consistently negative for antineutrophil cytoplasm antibodies (ANCA). A report of 3 cases and a review of the literature. Clin Exp Rheumatol 2001;19:541-9.
84. Birck R, Schmitt WH, Kaelsch IA, van der Woude FJ. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 2006;47:15-23.
85. Longford CA. Antineutrophil cytoplasm antibodies should not be used to guide treatment in Wegener's granulomatosis. Clin Exp Rheumatol 2004;22(Suppl 36):S3-6.
86. Niederstadt C, Happ T, Tatsis E, Schnabel A, Steinhoff J. Glomerular and tubular proteinuria as markers of nephropathy in rheumatoid arthritis. Rheumatology (Oxford) 1999;38:28-33.
87. Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int 2002;62:1732-42.
88. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089-100.
89. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005;16:763-73.